Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020
According to the recently published report Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020; Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 49 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes.
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.
The report Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020 outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 12, 5, 1, 12 and 8 respectively. Similarly, the universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Musculoskeletal Disorders, Genetic Disorders, Gastrointestinal and Respiratory which include indications Solid Tumor, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Bile Duct Cancer (Cholangiocarcinoma), Epithelial Ovarian Cancer, Pancreatic Cancer, Tenosynovial Giant Cell Tumor, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Breast Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Alzheimers Disease, Amyotrophic Lateral Sclerosis, Chronic Myelomonocytic Leukemia (CMML), Endometrial Cancer, Follicular Thyroid Cancer, Graft Versus Host Disease (GVHD), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medullary Thyroid Cancer, Metastatic Pancreatic Cancer, Neuroinflammation, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Pigmented Villonodular Synovitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Salivary Gland Cancer, Thyroid Cancer, Acral Lentiginous Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Asthma, Auto Inflammatory Disease, Bone Metastasis, Brenner Tumor, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Ependymoma, Esophageal Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Gliosarcoma, High-Grade Glioma, Hormone Sensitive Breast Cancer, Inflammation, Lentigo Maligna Melanoma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Liposarcoma, Lung Adenocarcinoma, Malignant Mesothelioma, Malignant Neoplasms, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Osteolysis, Osteoporosis, Osteosarcoma, Pain, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pheochromocytoma, Primary Progressive Multiple Sclerosis (PPMS), ), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Small-Cell Lung Cancer, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Tauopathies, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transformed Mycosis Fungoides, Uveal Melanoma and Von Hippel-Lindau Syndrome.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
According to the recently published report Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020; Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 49 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes.
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.
The report Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020 outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 12, 5, 1, 12 and 8 respectively. Similarly, the universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Musculoskeletal Disorders, Genetic Disorders, Gastrointestinal and Respiratory which include indications Solid Tumor, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Bile Duct Cancer (Cholangiocarcinoma), Epithelial Ovarian Cancer, Pancreatic Cancer, Tenosynovial Giant Cell Tumor, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Breast Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Alzheimers Disease, Amyotrophic Lateral Sclerosis, Chronic Myelomonocytic Leukemia (CMML), Endometrial Cancer, Follicular Thyroid Cancer, Graft Versus Host Disease (GVHD), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medullary Thyroid Cancer, Metastatic Pancreatic Cancer, Neuroinflammation, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Pigmented Villonodular Synovitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Salivary Gland Cancer, Thyroid Cancer, Acral Lentiginous Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Asthma, Auto Inflammatory Disease, Bone Metastasis, Brenner Tumor, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Ependymoma, Esophageal Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Gliosarcoma, High-Grade Glioma, Hormone Sensitive Breast Cancer, Inflammation, Lentigo Maligna Melanoma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Liposarcoma, Lung Adenocarcinoma, Malignant Mesothelioma, Malignant Neoplasms, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Osteolysis, Osteoporosis, Osteosarcoma, Pain, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pheochromocytoma, Primary Progressive Multiple Sclerosis (PPMS), ), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Small-Cell Lung Cancer, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Tauopathies, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transformed Mycosis Fungoides, Uveal Melanoma and Von Hippel-Lindau Syndrome.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
TABLE OF CONTENTS
Table of Contents
Introduction
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Overview
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Development
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Product Development Milestones
Appendix
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AB Science SA, H1 2020
Pipeline by Abbisko Therapeutics Co Ltd, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Apollomics Inc, H1 2020
Pipeline by BCI Pharma SA, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CrystalGenomics Inc, H1 2020
Pipeline by CTI BioPharma Corp, H1 2020
Pipeline by Deciphera Pharmaceuticals Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Elixiron Immunotherapeutics Inc, H1 2020
Pipeline by Elsalys Biotech SA, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Flavocure Biotech LLC, H1 2020
Pipeline by GigaGen Inc, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Pipeline by Hutchison MediPharma Ltd, H1 2020
Pipeline by ImmunoForge Co Ltd, H1 2020
Pipeline by Jiangsu Suzhong Pharmaceutical Group Co Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by NMS Group SpA, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Oncodesign SA, H1 2020
Pipeline by Oncology Venture A/S, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Plexxikon Inc, H1 2020
Pipeline by Provention Bio Inc, H1 2020
Pipeline by Samjin Pharm Co Ltd, H1 2020
Pipeline by Shattuck Labs Inc, H1 2020
Pipeline by SignalChem Lifesciences Corp, H1 2020
Pipeline by Suntec Medical (Taiwan) Inc, H1 2020
Pipeline by Syndax Pharmaceuticals Inc, H1 2020
Pipeline by The National Institute for Biotechnology in the Negev Ltd, H1 2020
Pipeline by Transcenta Holding Ltd, H1 2020
Pipeline by Turning Point Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Dormant Products, H1 2020 (Contd..5), H1 2020
Dormant Products, H1 2020 (Contd..6), H1 2020
Dormant Products, H1 2020 (Contd..7), H1 2020
Dormant Products, H1 2020 (Contd..8), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
Introduction
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Overview
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Development
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Product Development Milestones
Appendix
List Of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Companies, H1 2020 (Contd..10), H1 2020
Products under Development by Companies, H1 2020 (Contd..11), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AB Science SA, H1 2020
Pipeline by Abbisko Therapeutics Co Ltd, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Apollomics Inc, H1 2020
Pipeline by BCI Pharma SA, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CrystalGenomics Inc, H1 2020
Pipeline by CTI BioPharma Corp, H1 2020
Pipeline by Deciphera Pharmaceuticals Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Elixiron Immunotherapeutics Inc, H1 2020
Pipeline by Elsalys Biotech SA, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Flavocure Biotech LLC, H1 2020
Pipeline by GigaGen Inc, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Pipeline by Hutchison MediPharma Ltd, H1 2020
Pipeline by ImmunoForge Co Ltd, H1 2020
Pipeline by Jiangsu Suzhong Pharmaceutical Group Co Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by NMS Group SpA, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Oncodesign SA, H1 2020
Pipeline by Oncology Venture A/S, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Plexxikon Inc, H1 2020
Pipeline by Provention Bio Inc, H1 2020
Pipeline by Samjin Pharm Co Ltd, H1 2020
Pipeline by Shattuck Labs Inc, H1 2020
Pipeline by SignalChem Lifesciences Corp, H1 2020
Pipeline by Suntec Medical (Taiwan) Inc, H1 2020
Pipeline by Syndax Pharmaceuticals Inc, H1 2020
Pipeline by The National Institute for Biotechnology in the Negev Ltd, H1 2020
Pipeline by Transcenta Holding Ltd, H1 2020
Pipeline by Turning Point Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Dormant Products, H1 2020 (Contd..5), H1 2020
Dormant Products, H1 2020 (Contd..6), H1 2020
Dormant Products, H1 2020 (Contd..7), H1 2020
Dormant Products, H1 2020 (Contd..8), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020 (Contd..3), H1 2020
List Of Figures
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
RELATED REPORTS
Growth/Differentiation Factor 15 (Macrophage Inhibitory Cytokine 1 or NSAID Regulated Gene 1 Protein or Placental Bone Morphogenetic Protein or Prostate Differentiation Factor or GDF15) - Drugs in Development, 2021
Growth/Differentiation Factor 15 (Macrophage Inhibitory Cytokine 1 or NSAID Regulated Gene 1 Protein or Placental Bone Morphogenetic Protein or Prostate Differentiation Factor or GDF15) - Drugs in Development, 2021Growth/Differentiation Factor
View ReportLeukocyte Immunoglobulin Like Receptor Subfamily B Member 2 (CD85 Antigen Like Family Member D or Immunoglobulin Like Transcript 4 or Monocyte/Macrophage Immunoglobulin Like Receptor 10 or CD85d or LILRB2) - Drugs in Development, 2021
Leukocyte Immunoglobulin Like Receptor Subfamily B Member 2 (CD85 Antigen Like Family Member D or Immunoglobulin Like Transcript 4 or Monocyte/Macrophage Immunoglobulin Like Receptor 10 or CD85d or LILRB2) -
View ReportGlobal Granulocyte Macrophage Colony Stimulating Factor Market Research Report 2021-2025
In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Granulocyte Macrophage Colony Stimulating Factor Report by Material,
View ReportGranulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) - Drugs in Development, 2021
Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) - Drugs in Development, 2021Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) - Drugs in Development, 2021 provides
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
